$36.82
5.20%
Nasdaq, Nov 14, 10:15 pm CET
ISIN
US86366E1064
Symbol
GPCR

Structure Therapeutics Stock price

$36.82
+6.69 22.20% 1M
+13.01 54.61% 6M
+9.70 35.77% YTD
-0.87 2.31% 1Y
+21.82 145.47% 3Y
+21.82 145.47% 5Y
+21.82 145.47% 10Y
+21.82 145.47% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+1.82 5.20%
ISIN
US86366E1064
Symbol
GPCR
Industry

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$1.3b
Net debt
positive
Cash
$799.0m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
95.7%
Return on Equity
-14.2%
ROCE
-32.0%
ROIC
-2,836.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-246.4m | $-283.5m
EBIT
$-247.6m | $-278.6m
Net Income
$-210.7m | -
Free Cash Flow
$-196.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-74.3% | -80.3%
EBIT
-74.2% | -76.1%
Net Income
-90.6% | -
Free Cash Flow
-88.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.2
FCF per Share
-
Short interest
12.5%
Employees
199
Rev per Employee
$0.0
Show more

Is Structure Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Structure Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Structure Therapeutics forecast:

20x Buy
95%
1x Hold
5%

Analyst Opinions

21 Analysts have issued a Structure Therapeutics forecast:

Buy
95%
Hold
5%

Financial data from Structure Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
23% 23%
-
- Research and Development Expense 190 190
99% 99%
-
-246 -246
74% 74%
-
- Depreciation and Amortization 1.19 1.19
51% 51%
-
EBIT (Operating Income) EBIT -248 -248
74% 74%
-
Net Profit -211 -211
91% 91%
-

In millions USD.

Don't miss a Thing! We will send you all news about Structure Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Structure Therapeutics Stock News

Neutral
GlobeNewsWire
11 days ago
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025
Positive
The Motley Fool
2 months ago
The weight-management market is arguably the hottest therapeutic area in the industry right now. Investors seeking to capitalize on the rapid expansion of this niche can turn to established giants like Eli Lilly and Novo Nordisk.
Neutral
Seeking Alpha
2 months ago
Structure Therapeutics Inc. (NASDAQ:GPCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Raymond Stevens - CEO & Director Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everyone.
More Structure Therapeutics News

Company Profile

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.

Head office Cayman Islands
CEO Raymond Stevens
Employees 199
Founded 2019
Website structuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today